Xontogeny

A diverse pipeline of early-stage life sciences companies

Xontogeny has made a number of seed investments and continues to incubate a pipeline of early-stage life sciences companies across a wide variety of modalities and therapeutic areas. We typically do not communicate about our portfolio companies until they have received Series A financing, however we are happy to discuss our portfolio further if you are interested in collaboration, partnering or investment opportunities in our companies.

Our lead portfolio company, Landos BioPharma, is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases and completed a $60M Series B funding round in August 2019. Landos’ lead product, BT-11, is in Phase II studies for ulcerative colitis and Crohn’s disease.